Cargando…

Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients

This study aimed to analyse the diversity and taxonomic composition of the nasopharyngeal microbiota, to determine its association with COVID-19 clinical outcome. To study the microbiota, we utilized 16S rRNA sequencing of 177 samples that came from a retrospective cohort of COVID-19 hospitalized pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ventero, Maria Paz, Moreno-Perez, Oscar, Molina-Pardines, Carmen, Paytuví-Gallart, Andreu, Boix, Vicente, Escribano, Isabel, Galan, Irene, González-delaAleja, Pilar, López-Pérez, Mario, Sánchez-Martínez, Rosario, Merino, Esperanza, Rodríguez, Juan Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709923/
https://www.ncbi.nlm.nih.gov/pubmed/34963638
http://dx.doi.org/10.1016/j.jinf.2021.12.030
Descripción
Sumario:This study aimed to analyse the diversity and taxonomic composition of the nasopharyngeal microbiota, to determine its association with COVID-19 clinical outcome. To study the microbiota, we utilized 16S rRNA sequencing of 177 samples that came from a retrospective cohort of COVID-19 hospitalized patients. Raw sequences were processed by QIIME2. The associations between microbiota, invasive mechanical ventilation (IMV), and all-cause mortality were analysed by multiple logistic regression, adjusted for age, gender, and comorbidity. The microbiota α diversity indexes were lower in patients with a fatal outcome, whereas the β diversity analysis showed a significant clustering in these patients. After multivariate adjustment, the presence of Selenomonas spp., Filifactor spp., Actinobacillus spp., or Chroococcidiopsis spp., was associated with a reduction of more than 90% of IMV. Higher diversity and the presence of certain genera in the nasopharyngeal microbiota seem to be early biomarkers of a favourable clinical evolution in hospitalized COVID-19 patients.